These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 21691706)
1. Clinical implications for BRCA gene mutation in breast cancer. Xu J; Wang B; Zhang Y; Li R; Wang Y; Zhang S Mol Biol Rep; 2012 Mar; 39(3):3097-102. PubMed ID: 21691706 [TBL] [Abstract][Full Text] [Related]
2. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women. Comen E; Davids M; Kirchhoff T; Hudis C; Offit K; Robson M Breast Cancer Res Treat; 2011 Aug; 129(1):185-90. PubMed ID: 21394499 [TBL] [Abstract][Full Text] [Related]
3. High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors. Sanford RA; Song J; Gutierrez-Barrera AM; Profato J; Woodson A; Litton JK; Bedrosian I; Albarracin CT; Valero V; Arun B Cancer; 2015 Oct; 121(19):3422-7. PubMed ID: 26280679 [TBL] [Abstract][Full Text] [Related]
4. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Kuchenbaecker KB; Neuhausen SL; Robson M; Barrowdale D; McGuffog L; Mulligan AM; Andrulis IL; Spurdle AB; Schmidt MK; Schmutzler RK; Engel C; Wappenschmidt B; Nevanlinna H; Thomassen M; Southey M; Radice P; Ramus SJ; Domchek SM; Nathanson KL; Lee A; Healey S; Nussbaum RL; Rebbeck TR; Arun BK; James P; Karlan BY; Lester J; Cass I; ; Terry MB; Daly MB; Goldgar DE; Buys SS; Janavicius R; Tihomirova L; Tung N; Dorfling CM; van Rensburg EJ; Steele L; v O Hansen T; Ejlertsen B; Gerdes AM; Nielsen FC; Dennis J; Cunningham J; Hart S; Slager S; Osorio A; Benitez J; Duran M; Weitzel JN; Tafur I; Hander M; Peterlongo P; Manoukian S; Peissel B; Roversi G; Scuvera G; Bonanni B; Mariani P; Volorio S; Dolcetti R; Varesco L; Papi L; Tibiletti MG; Giannini G; Fostira F; Konstantopoulou I; Garber J; Hamann U; Donaldson A; Brewer C; Foo C; Evans DG; Frost D; Eccles D; ; Douglas F; Brady A; Cook J; Tischkowitz M; Adlard J; Barwell J; Ong KR; Walker L; Izatt L; Side LE; Kennedy MJ; Rogers MT; Porteous ME; Morrison PJ; Platte R; Eeles R; Davidson R; Hodgson S; Ellis S; Godwin AK; Rhiem K; Meindl A; Ditsch N; Arnold N; Plendl H; Niederacher D; Sutter C; Steinemann D; Bogdanova-Markov N; Kast K; Varon-Mateeva R; Wang-Gohrke S; Gehrig A; Markiefka B; Buecher B; Lefol C; Stoppa-Lyonnet D; Rouleau E; Prieur F; Damiola F; ; Barjhoux L; Faivre L; Longy M; Sevenet N; Sinilnikova OM; Mazoyer S; Bonadona V; Caux-Moncoutier V; Isaacs C; Van Maerken T; Claes K; Piedmonte M; Andrews L; Hays J; Rodriguez GC; Caldes T; de la Hoya M; Khan S; Hogervorst FB; Aalfs CM; de Lange JL; Meijers-Heijboer HE; van der Hout AH; Wijnen JT; van Roozendaal KE; Mensenkamp AR; van den Ouweland AM; van Deurzen CH; van der Luijt RB; ; Olah E; Diez O; Lazaro C; Blanco I; Teulé A; Menendez M; Jakubowska A; Lubinski J; Cybulski C; Gronwald J; Jaworska-Bieniek K; Durda K; Arason A; Maugard C; Soucy P; Montagna M; Agata S; Teixeira MR; ; Olswold C; Lindor N; Pankratz VS; Hallberg E; Wang X; Szabo CI; Vijai J; Jacobs L; Corines M; Lincoln A; Berger A; Fink-Retter A; Singer CF; Rappaport C; Kaulich DG; Pfeiler G; Tea MK; Phelan CM; Mai PL; Greene MH; Rennert G; Imyanitov EN; Glendon G; Toland AE; Bojesen A; Pedersen IS; Jensen UB; Caligo MA; Friedman E; Berger R; Laitman Y; Rantala J; Arver B; Loman N; Borg A; Ehrencrona H; Olopade OI; Simard J; Easton DF; Chenevix-Trench G; Offit K; Couch FJ; Antoniou AC; Breast Cancer Res; 2014 Dec; 16(6):3416. PubMed ID: 25919761 [TBL] [Abstract][Full Text] [Related]
5. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. Atchley DP; Albarracin CT; Lopez A; Valero V; Amos CI; Gonzalez-Angulo AM; Hortobagyi GN; Arun BK J Clin Oncol; 2008 Sep; 26(26):4282-8. PubMed ID: 18779615 [TBL] [Abstract][Full Text] [Related]
6. CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer. Plevova P; Cerna D; Balcar A; Foretova L; Zapletalova J; Silhanova E; Curik R; Dvorackova J Neoplasma; 2010; 57(4):325-32. PubMed ID: 20429623 [TBL] [Abstract][Full Text] [Related]
7. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer. Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863 [TBL] [Abstract][Full Text] [Related]
8. Comparison of nodal metastasis between BRCA mutation carriers and non-BRCA mutation carriers with breast cancer. Noori SF; Gangi A; Nelson ME; Choi M; Mirzadehgan P; Bonk AK; Mirocha J; Amersi F; Giuliano AE Ann Surg Oncol; 2014 Oct; 21(10):3324-9. PubMed ID: 25047471 [TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study. Hussein IA; Ahmed ST; Hameedi AD; Naji RZ; Alharbawi L; Alkhaytt M; Pity IS Asian Pac J Cancer Prev; 2020 Apr; 21(4):1025-1029. PubMed ID: 32334465 [TBL] [Abstract][Full Text] [Related]
10. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Gonzalez-Angulo AM; Timms KM; Liu S; Chen H; Litton JK; Potter J; Lanchbury JS; Stemke-Hale K; Hennessy BT; Arun BK; Hortobagyi GN; Do KA; Mills GB; Meric-Bernstam F Clin Cancer Res; 2011 Mar; 17(5):1082-9. PubMed ID: 21233401 [TBL] [Abstract][Full Text] [Related]
11. Clinical and pathologic differences between BRCA1-, BRCA2-, and non-BRCA-associated breast cancers in a multiracial developing country. Yip CH; Taib NA; Choo WY; Rampal S; Thong MK; Teo SH World J Surg; 2009 Oct; 33(10):2077-81. PubMed ID: 19649760 [TBL] [Abstract][Full Text] [Related]
12. Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. Guzmán-Arocho YD; Rosenberg SM; Garber JE; Vardeh H; Poorvu PD; Ruddy KJ; Kirkner G; Snow C; Tamimi RM; Peppercorn J; Schapira L; Borges VF; Come SE; Brachtel EF; Marotti JD; Warner E; Partridge AH; Collins LC Br J Cancer; 2022 Feb; 126(2):302-309. PubMed ID: 34703009 [TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less. Bayraktar S; Amendola L; Gutierrez-Barrera AM; Hashmi SS; Amos C; Gambello M; Ready KJ; Arun B Breast; 2014 Dec; 23(6):770-4. PubMed ID: 25231195 [TBL] [Abstract][Full Text] [Related]
15. Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer. Danzinger S; Tan YY; Rudas M; Kastner MT; Weingartshofer S; Muhr D; Singer CF BMC Cancer; 2019 Jul; 19(1):695. PubMed ID: 31307407 [TBL] [Abstract][Full Text] [Related]
16. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype. Wiese DA; Thaiwong T; Yuzbasiyan-Gurkan V; Kiupel M BMC Cancer; 2013 Sep; 13():403. PubMed ID: 24004841 [TBL] [Abstract][Full Text] [Related]
17. Genotype in BRCA-associated breast cancers. Meric-Bernstam F; Gutierrez-Barrera AM; Litton J; Mellor-Crummey L; Ready K; Gonzalez-Angulo AM; Lu KH; Hortobagyi GN; Arun BK Breast J; 2013; 19(1):87-91. PubMed ID: 23231005 [TBL] [Abstract][Full Text] [Related]
18. Pathological characteristics of BRCA-associated breast cancers in Hispanics. Lagos-Jaramillo VI; Press MF; Ricker CN; Dubeau L; Mai PL; Weitzel JN Breast Cancer Res Treat; 2011 Nov; 130(1):281-9. PubMed ID: 21604016 [TBL] [Abstract][Full Text] [Related]
19. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Vollebergh MA; Lips EH; Nederlof PM; Wessels LF; Wesseling J; Vd Vijver MJ; de Vries EG; van Tinteren H; Jonkers J; Hauptmann M; Rodenhuis S; Linn SC Breast Cancer Res; 2014 May; 16(3):R47. PubMed ID: 24887359 [TBL] [Abstract][Full Text] [Related]
20. Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status. Murphy NC; Biankin AV; Millar EK; McNeil CM; O'Toole SA; Segara D; Crea P; Olayioye MA; Lee CS; Fox SB; Morey AL; Christie M; Musgrove EA; Daly RJ; Lindeman GJ; Henshall SM; Visvader JE; Sutherland RL Int J Cancer; 2010 Mar; 126(6):1445-53. PubMed ID: 19676041 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]